Toxicological evaluation of live attenuated, cold-adapted H5N1 vaccines in ferrets

被引:23
作者
Jin, H. [1 ]
Manetz, S. [2 ]
Leininger, J. [2 ]
Luke, C. [3 ]
Subbarao, K. [3 ]
Murphy, B. [3 ]
Kemble, G. [1 ]
Coelingh, K. L. [2 ]
机构
[1] Medimmune Inc, Mountain View, CA 94043 USA
[2] Medimmune Inc, Gaithersburg, MD 20878 USA
[3] NIAID, Infect Dis Lab, NIH, Bethesda, MD 20892 USA
关键词
influenza; vaccine; H5N1; toxicology; ferrets; INFLUENZA-VIRUS VACCINE; A VIRUS; TRIVALENT; CHILDREN; INTRANASAL; PROTECTION; EFFICACY; VOLUNTEERS; MICE;
D O I
10.1016/j.vaccine.2007.10.032
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Live attenuated influenza vaccines (LAIV) have several attributes related to safety, immunogenicity, cross-protection against antigenic drift strains, high yield and needle-free administration that make them attractive candidates for control of pandemic influenza. H5N1 LAIV vaccine candidates are attenuated in ferrets, chickens and mice. These vaccine candidates were further characterized in the ferret model to evaluate their toxicity at doses comparable to seasonal LAIV and at doses up to 100-fold higher. The results demonstrated that H5N1 LAIV, even when administered at high doses, is restricted in replication in the lower respiratory tract of ferrets. However, intranasal administration of 0.5 mL can result in deposition of H5N1 LAIV in the ferret lung, where it induces a pulmonary inflammatory response in the absence of significant local replication of the vaccine virus. Thus, smaller vaccine dose volumes should be considered for evaluation of LAIV in animal models. (c) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:8664 / 8672
页数:9
相关论文
共 23 条
[1]   Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine [J].
Belshe, RB ;
Gruber, WC ;
Mendelman, PM ;
Mehta, HB ;
Mahmood, K ;
Reisinger, K ;
Treanor, J ;
Zangwill, Z ;
Hayden, FG ;
Bernstein, DI ;
Kotloff, K ;
King, J ;
Piedra, PA ;
Block, SL ;
Yan, LH ;
Wolff, M .
JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (03) :1133-1137
[2]   The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children [J].
Belshe, RB ;
Mendelman, PM ;
Treanor, J ;
King, J ;
Gruber, WC ;
Piedra, P ;
Bernstein, DI ;
Hayden, FG ;
Kotloff, K ;
Zangwill, K ;
Iacuzio, D ;
Wolff, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (20) :1405-1412
[3]   Live attenuated versus inactivated influenza vaccine in infants and young children [J].
Belshe, Robert B. ;
Edwards, Kathryn M. ;
Vesikari, Timo ;
Black, Steven V. ;
Walker, Robert E. ;
Hultquist, Micki ;
Kemble, George ;
Connor, Edward M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (07) :685-696
[4]   ANALYSIS OF VIRUS AND HOST FACTORS IN A STUDY OF A-PEKING-2-79 (H3N2) COLD-ADAPTED VACCINE RECOMBINANT IN WHICH VACCINE-ASSOCIATED ILLNESS OCCURRED IN NORMAL VOLUNTEERS [J].
BETTS, RF ;
DOUGLAS, RG ;
MAASSAB, HF ;
DEBORDE, DC ;
CLEMENTS, ML ;
MURPHY, BR .
JOURNAL OF MEDICAL VIROLOGY, 1988, 26 (02) :175-183
[5]   Comparison of the clearance of radiolabelled nose drops and nasal spray as mucosally delivered vaccine [J].
Bryant, ML ;
Brown, P ;
Gurevich, N ;
McDougall, IR .
NUCLEAR MEDICINE COMMUNICATIONS, 1999, 20 (02) :171-174
[6]   Genetic and phenotypic stability of cold-adapted influenza viruses in a trivalent vaccine administered to children in a day care setting [J].
Buonagurio, DA ;
O'Neill, RE ;
Shutyak, L ;
D'Arco, GA ;
Bechert, TM ;
Kazachkov, Y ;
Wang, HP ;
DeStefano, J ;
Coelingh, KL ;
August, M ;
Parks, CL ;
Zamb, TJ ;
Sidhu, MS ;
Udem, SA .
VIROLOGY, 2006, 347 (02) :296-306
[7]   Direct and total effectiveness of the intranasal, live-attenuated, trivalent cold-adapted influenza virus vaccine against the 2000-2001 influenza A(H1N1) and B epidemic in healthy children [J].
Gaglani, MJ ;
Piedra, PA ;
Herschler, GB ;
Griffith, ME ;
Kozinetz, CA ;
Riggs, MW ;
Fewlass, C ;
Halloran, ME ;
Longini, IM ;
Glezen, WP .
ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE, 2004, 158 (01) :65-73
[8]   Efficacy of trivalent, cold-adapted, influenza virus vaccine against influenza A (Fujian), a drift variant, during 2003-2004 [J].
Halloran, M. Elizabeth ;
Piedra, Pedro A. ;
Longini, Ira A., Jr. ;
Gaglani, Manjusha J. ;
Schmotzer, Brian ;
Fewlass, Charles ;
Herschler, Gayla B. ;
Glezen, W. Paul .
VACCINE, 2007, 25 (20) :4038-4045
[9]   Estimating efficacy of trivalent, cold-adapted, influenza virus vaccine (CAIV-T) against influenza A (H1N1) and B using surveillance cultures [J].
Halloran, ME ;
Longini, IM ;
Gaglani, MJ ;
Piedra, PA ;
Chu, H ;
Herschler, GB ;
Glezen, WP .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 2003, 158 (04) :305-311
[10]   THE TOXICITY OF INFLUENZA VIRUSES [J].
HENLE, W ;
HENLE, G .
SCIENCE, 1945, 102 (2651) :398-400